Carbohydrate antigen 15.3 in Breast Cancer monitoring
DOI:
https://doi.org/10.5281/zenodo.14908374Keywords:
Follow-up Studies, Breast Neoplasms, Tumor BiomarkersAbstract
Introduction: Carbohydrate antigen 15.3 is related to polymorphic epithelial mucin, a marker of breast cancer. Levels higher than 30 U / mL are associated with lower overall survival.
Objective: To describe the use of carbohydrate antigen 15.3 in the follow-up of patients with breast cancer, after being treated with chemotherapy, at Vladimir Ilich Lenin Hospital in Holguín, from March to November 2020.
Methods: A descriptive, cross-sectional retrospective observational study was carried out in a universe of 78 patients, from which 30 were selected through an intentional non-probabilistic sampling. The variables analyzed in correspondence with the research were: age, CA15.3 value before and after treatment, as well as findings of recurrences on computerized axial tomography. Descriptive statistic was used.
Results: The predominant age interval was between 62 and 70 years (33.3%). Before chemotherapy, the serum levels of carbohydrate antigen 15.3 were normal (66.6%), and after treatment high levels of this tumor marker were detected (63.3%). Regarding the findings of the computerized axial tomography, they were negative for the presence of recurrences (53.3%).
Conclusions: The values of carbohydrate antigen 15.3 used in the elderly patients with breast cancer were normal; however, after chemotherapy treatment they increased, with no significant findings on computerized axial tomography.
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 [citado 18/03/2021]; 71(7): 7-33. Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21654
Freedman RA, Keating NL, Partridge AH. Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop: A Review. JAMA Oncol. 2017[citado 18/03/2021]; 3(1):402. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27892991/
Litviakov NV, Bychkov VA, Stakheeva MN, Ibragimova MK, Tsyganov MM, Gaptulbarova KA. Breast tumor cell subpopulations with expression of the OCT4 proteins. J Mol Hist.2020 [citado 18/01/2020]; 51(6):717-728. Disponible en: https://link.springer.com/article/10.1007/s10735-020-09917-1
Cuba. Ministerio de Salud Pública. Anuario estadístico de Cuba. La Habana: MINSAP; 2020.
Pulido C, Vendrell I, Ferreira AR, Casimiro S, Mansinho A, Alho I, Costa L. Bone metastasis risk factors in breast cancer. Ecancermedicalscience. 2017[citado 18/03/2021]; 11(3):7-15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295847/
Padera TP, Meijer EF, Munn LL. The Lymphatic System in Disease Processes and Cancer Progression. AnnuRevBiomedEng. 2016[citado 18/03/2021]; 11(18):125-58. Disponible en: https://www.annualreviews.org/doi/full/10.1146/annurev-bioeng-112315-031200
Barrios E, Garau M. Cáncer: magnitud del problema en el mundo y en Uruguay, aspectos epidemiológicos. RevAn Facultad Med. 2017 [citado 18/03/2021]; 4(1):9-46. Disponible en: http://rue.edu.uy/index.php/rue/article/view/04007
De Groot AF, Kuijpers CJ, Kroep JR. CDK4/6 inhibition in early and metastatic breast cancer: a review. Cancer Treat Rev. 2017 [citado 18/03/2021]; 60(8):130-138. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0305737217301482
Pérez-Parra M, Peña-Pérez OR, Batista-Ferrer A, Álvarez-Yabor Vd, Ricardo-Peña A. Caracterización clínica y anatomopatológica de pacientes con cáncer de mama atendidas en el hospital “Ernesto Guevara de la Serna”. Rev. electron. Zoilo. 2018[citado 25/07/2021];43(5). Disponible en: http://www.revzoilomarinello.sld.cu/index.php/zmv/article/view/1382
Citagez B, Yigit B, Capkinoglu E, Yetkin SG. Management of breast cancer during the COVID-19 pandemic. Sisli Etfal Hastan Tip Bul. 2020 [citado 18/03/2021]; 54(2): 132-135. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326681/
Mudduwa L, Wijayaratne G, Peiris H, Gunasekera S,Deepthika Abeysiriwardhana D, Liyanage N. Elevated pre-surgical ca15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? Int J Womens Health. 2018 [citado 18/03/2021];10(1): 329-335. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027693/
Göktaş I, Cayvarli H. The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer. Mol Imaging Radionucl Ther. 2018 [citado 18/03/2021]; 27(1):3-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790971/
Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V. Barak V, et al. An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Manag Res.2018 [citado 18/03/2021];10(4): 6879–86. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300365/
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Revista HolCien
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Centro Provincial de Información de Ciencias Médicas. Universidad de Ciencias Médicas de Holguín. Cuba.
Política de acceso y distribución
El total de los artículos publicados son contribuciones de acceso abierto, que se distribuyen según los términos de la Licencia Creative Commons Atribución–NoComercial 4.0 que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
